Participants in the pivotal SURMOUNT-1 trial who took the highest dose of tirzepatide lost an average of 22.5 percent of their body weight over 72 weeks, the largest weight loss ever recorded in an FDA trial for a non-surgical obesity treatment. That’s why Zepbound weight loss results have reshaped how clinicians and patients think about medical obesity care. Zepbound is the brand name for tirzepatide approved specifically for chronic weight management in adults, and its combination of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor activity represents a new mechanism in the weight-loss drug class. For the broader context of medical weight loss, see our wellness guide.
How Zepbound Works in the Body
Zepbound contains tirzepatide, a once-weekly injectable that activates two different gut hormone receptors simultaneously: GIP and GLP-1. These hormones are released naturally when you eat, and they signal your brain to reduce appetite, slow gastric emptying, and improve the body’s insulin response to food. By amplifying both signals, tirzepatide produces stronger appetite suppression and greater weight loss than single-agonist GLP-1 drugs.
The dual mechanism matters clinically. GLP-1 alone, as in Wegovy, produces weight loss through appetite reduction. Adding GIP contributes additional metabolic effects that researchers believe enhance energy expenditure and improve fat oxidation. The full mechanistic picture is still being studied, but the trial data show consistently greater weight loss with tirzepatide than semaglutide. Compare mechanisms in our Wegovy vs Mounjaro article.
What the Trial Data Actually Shows
The SURMOUNT-1 trial, published in the New England Journal of Medicine in 2022, enrolled 2,539 adults with obesity or overweight with at least one weight-related comorbidity but without type 2 diabetes. Over 72 weeks, participants randomized to tirzepatide lost an average of 15 percent of body weight on the 5 mg dose, 19.5 percent on 10 mg, and 22.5 percent on 15 mg. Placebo participants lost just 2.4 percent.
SURMOUNT-2 extended the evidence to adults with both obesity and type 2 diabetes, showing weight loss of 12.8 percent at the 10 mg dose and 14.7 percent at the 15 mg dose — still robust though lower than in non-diabetic patients. More recently, the SURMOUNT-5 head-to-head trial against semaglutide showed tirzepatide producing significantly greater weight loss than Wegovy at comparable doses.
Dosing and Titration Schedule
Zepbound is injected once weekly, subcutaneously, usually in the abdomen, thigh, or upper arm. Patients start at 2.5 mg weekly for the first four weeks, then titrate to 5 mg for the next four weeks. Doses can increase every four weeks to 7.5 mg, 10 mg, 12.5 mg, and a maximum of 15 mg weekly, depending on tolerance and response.
Not every patient needs the maximum dose. Many respond well at 5 mg or 10 mg. Prescribers typically adjust based on weight loss progress, side effect tolerability, and patient goals. For detailed dose scheduling, see our Zepbound dose schedule guide and Zepbound dosing guide.
What to Expect in the First Six Months
Most patients notice appetite reduction within the first week or two, often described as feeling full faster and losing interest in high-calorie snacks. Meaningful weight loss typically appears by week four to six, accelerating through the titration period. On average, trial participants lost 5 to 7 percent of body weight by week 12 and 15 to 20 percent by weeks 40 to 52.
Weight loss is not linear. Patients commonly experience two or three weeks of plateau followed by renewed progress, often tied to dose escalations. Full plateau and body weight stabilization typically occur around month 18 to 24 for patients on maintenance therapy, though individual variation is substantial.
Common Side Effects
The most frequently reported Zepbound side effects are gastrointestinal: nausea, diarrhea, constipation, vomiting, indigestion, and abdominal pain. In SURMOUNT-1, nausea affected roughly 29 percent of patients on 15 mg tirzepatide, typically during dose escalation. Most gastrointestinal side effects are mild to moderate and diminish over weeks to months as the body adjusts.
Less common but more serious potential side effects include pancreatitis, gallbladder disease, acute kidney injury from dehydration, and severe allergic reactions. Rare reports of suicidal ideation during GLP-1 treatment prompted the FDA to investigate, though large database studies have not confirmed a causal link. For complete side-effect information, see our tirzepatide side effects article.
Who Is a Candidate for Zepbound
FDA approval limits Zepbound to adults with a body mass index (BMI) of 30 or greater (obesity) or a BMI of 27 or greater (overweight) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea. Candidates should also be willing to make diet and exercise changes, since the drug is approved as an adjunct to lifestyle modification, not a replacement for it.
Patients with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, severe gastrointestinal disease, or active pancreatitis should not take Zepbound. Pregnant women should not use it. Your prescriber will review your complete medical history before prescribing.
What Happens When You Stop Zepbound
Real-world and trial data both show that weight regain is common when tirzepatide is discontinued. The SURMOUNT-4 trial specifically studied this question: participants who stopped tirzepatide after 36 weeks regained about 14 percent of the weight they had lost over the next 52 weeks, while those who continued treatment maintained or further reduced their weight.
This finding mirrors what researchers have long understood about obesity medications generally. Obesity is a chronic condition, and treatment that stops produces rebound much like stopping blood pressure medication produces rebound hypertension. For patients considering long-term commitment, the data support continuing therapy indefinitely for most responders.
Cost and Access
Zepbound’s list price sits near $1,060 per month, though the Lilly Zepbound Savings Card can reduce the commercially insured copay to as low as $25 per monthly fill. Lilly Direct offers single-dose Zepbound vials at a self-pay price near $349 per month for patients without covered access. Insurance coverage has been expanding but remains inconsistent — see our Zepbound cost without insurance guide and Zepbound price breakdown for details.
Frequently Asked Questions
How fast does Zepbound work for weight loss?
Most patients notice appetite reduction within the first one to two weeks, with measurable weight loss appearing by week four. Trial data show an average of 5 to 7 percent body weight loss by week 12 and 15 to 20 percent by 40 to 52 weeks for patients on higher doses.
How much weight can you lose on Zepbound?
In SURMOUNT-1, the average weight loss at 72 weeks was 22.5 percent of body weight on the 15 mg dose. Individual results vary significantly — some patients lose 25 percent or more, while others lose 10 to 12 percent.
Do you gain weight back after stopping Zepbound?
Yes, most patients regain a significant portion of the lost weight after stopping. SURMOUNT-4 showed about 14 percent weight regain in the year following discontinuation. Obesity experts generally treat Zepbound as long-term therapy rather than a short-term cycle.
Is Zepbound better than Wegovy for weight loss?
Head-to-head data from SURMOUNT-5 showed tirzepatide (Zepbound) producing greater average weight loss than semaglutide (Wegovy) at comparable maintenance doses. Individual response varies, and side effect profiles differ slightly between the drugs.
Who shouldn’t take Zepbound?
People with a personal or family history of medullary thyroid carcinoma, MEN2 syndrome, active pancreatitis, or severe gastrointestinal conditions should not take Zepbound. Pregnant or breastfeeding women and anyone with a documented allergy to tirzepatide should also avoid it.
The Bottom Line on Zepbound for Weight Loss
Zepbound has produced the largest average weight-loss outcomes of any FDA-approved obesity medication to date, and for many patients it represents a legitimate shift in what is medically achievable without surgery. The drug works best as part of an ongoing treatment plan that includes dietary changes, physical activity, and regular medical follow-up. Expect gradual titration, manageable side effects during dose escalation, and weight loss that accelerates over the first 40 to 52 weeks. Stopping the drug typically leads to weight regain, so plan for extended use as part of chronic obesity care rather than a short-term intervention. Work closely with your prescriber to match the dose to your response and tolerability.